This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

HeartBeam Receives Nasdaq Notice on Minimum Bid Price

Tipranks - Fri Jul 3, 4:06PM CDT

4th of July Sale - 70% Off

HeartBeam ( (BEAT) ) has issued an update.

On June 30, 2026, HeartBeam received a Nasdaq deficiency notice after its common stock closed below the $1.00 minimum bid price for 30 consecutive business days, putting it out of compliance with Capital Market listing rules. The stock remains listed while the company has until December 28, 2026, to restore the bid price to at least $1.00 for ten straight sessions, or potentially seek an additional 180-day grace period.

HeartBeam plans to closely monitor its share price and consider options to regain compliance, but it acknowledges there is no certainty it will succeed within the allowed timeframe. Failure to meet the requirement could trigger a delisting notice, after which the company would have the right to appeal to a Nasdaq hearings panel, elevating risk for shareholders and potentially constraining future capital-raising flexibility.

The most recent analyst rating on (BEAT) stock is a Buy
with a $2.50 price target.
To see the full list of analyst forecasts on HeartBeam stock,
see the BEAT Stock Forecast page.

Spark’s Take on BEAT Stock

According to Spark, TipRanks’ AI Analyst, BEAT is a Neutral.

BEAT scores low primarily due to very weak financial performance (no revenue, large ongoing losses, persistent cash burn, and sharply reduced equity). Technicals also remain bearish with the price below all key moving averages despite oversold readings. Offsetting factors include improved runway and reduced cash outflow guidance from the latest earnings update, plus strategically positive corporate moves, but execution and financing risks remain significant.

To see Spark’s full report on BEAT stock,
click here.

More about HeartBeam

HeartBeam, Inc. operates in the medical technology sector, focusing on cardiac diagnostics supported by its common stock listing on The Nasdaq Capital Market. The company’s shares, with a par value of $0.0001 per share, are subject to Nasdaq’s continued listing standards, including minimum bid price requirements that can influence investor confidence and market access.

Average Trading Volume: 961,380

Technical Sentiment Signal: Sell

Current Market Cap: $40.48M

For detailed information about BEAT stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.